Drug Profile
Research programme: infectious disease therapeutics - Johnson & Johnson
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Developer Johnson & Johnson; National Institutes of Health (USA); University of California, San Diego; Walter and Eliza Hall Institute of Medical Research
- Class Antimalarials; Antiparasitics; Antituberculars; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chagas disease; Malaria; Tuberculosis
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Chagas-disease in USA
- 28 Jul 2021 No recent reports of development identified for research development in Malaria in USA
- 28 Jul 2021 No recent reports of development identified for research development in Tuberculosis in USA